The MEST score provides earlier risk prediction in lgA nephropathy

Kidney International

Volumn 89, Issue 1, 2016, Pages 167-175

  Barbour, Sean J ^a,b,c   Espino Hernandez, Gabriela ^b   Reich, Heather N ^d   Coppo, Rosanna ^e   Roberts, Ian S D ^f   Feehally, John ^g   Herzenberg, Andrew M ^d   Cattran, Daniel C ^d   Bavbek, N ^h   Cook, T ^h   Troyanov, S ^h,h   Alpers, C ^h   Amore, A ^h,h   Barratt, J ^h   Berthoux, F ^h   Bonsib, S ^h   Bruijn, J ^h,h   D'Agati, V ^h   D'Amico, G ^h   Emancipator, S ^h   Emmal, F ^h   Ferrario, F ^h,h,h   Fervenza, F ^h   Florquin, S ^h   Fogo, A ^h   Geddes, C ^h,h   Groene, H ^h   Haas, M ^h   Hill, P ^h   Hogg, R ^h   Hsu, S ^h   Hunley, T ^h   Hladunewich, M ^h   Jennette, C ^h   Joh, K ^h   Julian, B ^h   Kawamura, T ^h   Lai, F ^h   Leung, C ^h   Li, L ^h   Li, P ^h   Liu, Z ^h   Massat, A ^h   Mackinnon, B ^h   Mezzano, S ^h   Schena, F ^h   Tomino, Y ^h   Walker, P ^h   Wang, H ^h   Weening, J ^h   Yoshikawa, N ^h   Zhang, H ^h   Coppo, R ^h   Cattran, D C ^h   Cook, H T ^h   Feehally, J ^h   Roberts, I ^h   Tesar, V ^h   Maixnerova, D ^h   Lundberg, S ^h   Gesualdo, L ^h   Emma, F ^h   Fuiano, L ^h   Beltrame, G ^h   Rollino, C ^h   Camilla, R ^h   Peruzzi, L ^h   Praga, M ^h   Feriozzi, S ^h   Polci, R ^h   Segoloni, G ^h   Colla, L ^h   Pani, A ^h   Angioi, A ^h   Piras, L ^h   Cancarini, G ^h   Ravera, S ^h   Durlik, M ^h   Moggia, E ^h   Ballarin, J ^h   Di Giulio, S ^h   Pugliese, F ^h   Serriello, I ^h   Caliskan, Y ^h   Sever, M ^h   Kilicaslan, I ^h   Locatelli, F ^h   Del Vecchio, L ^h   Wetzels, J F M ^h   Peters, H ^h   Berg, U ^h   Carvalho, F ^h   Da Costa Ferreira, A C ^h   Maggio, M ^h   Wiecek, A ^h   Ots Rosenberg, M ^h   Magistroni, R ^h   Topaloglu, R ^h   Bilginer, Y ^h   D'Amico, M ^h   Stangou, M ^h   Giacchino, F ^h   Goumenos, D ^h   Kalliakmani, P ^h   Gerolymos, M ^h   Galesic, K ^h   Siamopoulos, K ^h   Balafa, O ^h   Galliani, M ^h   Stratta, P ^h   Quaglia, M ^h   Bergia, R ^h   Cravero, R ^h   Salvadori, M ^h   Cirami, L ^h   Fellstrom, B ^h   Kloster Smerud, H ^h   Stellato, T ^h   Egido, J ^h   Martin, C ^h   Floege, J ^h   Eitner, F ^h   Lupo, A ^h   Bernich, P ^h   Mene P ^h   Morosetti, M ^h   Van Kooten, C ^h   Rabelink, T ^h   Reinders, M E J ^h   Boria Grinyo, J M ^h   Cusinato, S ^h   Benozzi, L ^h   Savoldi, S ^h   Licata, C ^h   Mizerska Wasiak, M ^h   Martina, G ^h   Messuerotti, A ^h   Dal Canton, A ^h   Esposito, C ^h   Migotto, C ^h   Triolo, G ^h   Mariano, F ^h   Pozzi, C ^h   Boero, R ^h   Bellur, S ^h   Mazzucco, G ^h   Giannakakis, C ^h   Honsova, E ^h   Sundelin, B ^h   Di Palma, A M ^h   Gutierrez E ^h   Asunis, A M ^h   Tardanico, R ^h   Perkowska Ptasinska, A ^h   Arce Terroba, J ^h   Fortunato, M ^h   Pantzaki, A ^h   Ozluk, Y ^h   Steenbergen, E ^h   Soderberg, M ^h   Riispere, Z ^h   Furci, L ^h   Orhan, D ^h   Kipgen, D ^h   Casartelli, D ^h   Galesic Ljubanovic, D ^h   Gakiopoulou, H ^h   Bertoni, E ^h   Cannata Ortiz, P ^h   Karkoszka, H ^h   Groene, H J ^h   Stoppacciaro, A ^h   Bajema, I ^h   Fulladosa Oliveras, X ^h   Ioachim, E ^h   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC Provincial Renal Agency   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Regina Margherita University Children Hospital   (Italy)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g LEICESTER GENERAL HOSPITAL   (United Kingdom)

^h NONE

Author keywords

glomerular disease; IgA nephropathy; renal pathology

Indexed keywords

ADULT; ARTICLE; CALIBRATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; MEST SCORE; NORTH AMERICAN; PRIORITY JOURNAL; PROTEINURIA; SCLEROSIS; SCORING SYSTEM; SEGMENTAL SCLEROSIS; VALIDATION PROCESS; ATROPHY; BIOPSY; CLASSIFICATION; DISEASE COURSE; FIBROSIS; FOLLOW UP; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT;

ADULT; ATROPHY; BIOPSY; DISEASE PROGRESSION; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MESANGIAL CELLS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT;

EID: 84945559550     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.322     Document Type: Article

References (36)

1. D.C. Cattran, R. Coppo, H.T. Cook, and et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Kidney Int 76 2009 534 545
2. R. Coppo, S. Troyanov, S. Bellur, and et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments Kidney Int 86 2014 828 836
3. A.M. Herzenberg, A.B. Fogo, H.N. Reich, and et al. Validation of the Oxford classification of IgA nephropathy Kidney Int 80 2011 310 317
4. I.S. Roberts, H.T. Cook, S. Troyanov, and et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Kidney Int 76 2009 546 556
5. J. Lv, S. Shi, D. Xu, and et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis Am J Kidney Dis 62 2013 891 899
6. H.N. Reich, S. Troyanov, J.W. Scholey, and et al. Remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 2007 3177 3183
7. S. Tanaka, T. Ninomiya, R. Katafuchi, and et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy Clin J Am Soc Nephrol 8 2013 2082 2090
8. W. Le, S. Liang, Y. Hu, and et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population Nephrol Dial Transplant 27 2012 1479 1485
9. S.J. Barbour, and H.N. Reich Risk stratification of patients with IgA nephropathy Am J Kidney Dis 59 2012 865 873
10. L.P. Bartosik, G. Lajoie, L. Sugar, and et al. Predicting progression in IgA nephropathy Am J Kidney Dis 38 2001 728 735
11. B. Mackinnon, E.P. Fraser, D.C. Cattran, and et al. Validation of the Toronto formula to predict progression in IgA nephropathy Nephron Clin Pract 109 2008 c148 c153
12. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for Glomerulonephritis Kidney Int Suppl 2 2012 139 274
13. M. Goto, T. Kawamura, K. Wakai, and et al. Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm Nephrol Dial Transplant 24 2009 1242 1247
14. M. Goto, K. Wakai, T. Kawamura, and et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study Nephrol Dial Transplant 24 2009 3068 3074
15. K. Wakai, T. Kawamura, M. Endoh, and et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study Nephrol Dial Transplant 21 2006 2800 2808
16. F. Berthoux, H. Mohey, B. Laurent, and et al. Predicting the risk for dialysis or death in IgA nephropathy J Am Soc Nephrol 22 2011 752 761
17. M. Walsh, A. Sar, D. Lee, and et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy Clin J Am Soc Nephrol 5 2010 425 430
18. D.Z. Cherney, B. Zinman, C.R. Kennedy, and et al. Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus Kidney Int 84 2013 1246 1253
19. J. Reiser, and P. Mundel Dual effects of RAS blockade on blood pressure and podocyte function Curr Hypertens Rep 9 2007 403 408
20. P. Ruggenenti, A. Perna, G. Gherardi, and et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kidney Dis 35 2000 1155 1165
21. M. Praga, E. Gutierrez, E. Gonzalez, and et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 2003 1578 1583
22. P.K. Li, C.B. Leung, K.M. Chow, and et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 2006 751 760
23. C. Manno, D.D. Torres, M. Rossini, and et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 2009 3694 3701
24. J. Lv, H. Zhang, Y. Chen, and et al. Combination therapy of prednisone and ACE inhibitor vs. ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial Am J Kidney Dis 53 2009 26 32
25. C. Pozzi, S. Andrulli, L. Del Vecchio, and et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial J Am Soc Nephrol 15 2004 157 163
26. V. Tesar, S. Troyanov, S. Bellur, and et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA Study J Am Soc Nephrol 26 2015 2248 2258
27. E. Alamartine, C. Sauron, B. Laurent, and et al. The use of the oxford classification of IgA nephropathy to predict renal survival Clin J Am Soc Nephrol 6 2011 2384 2388
28. S.F. Shi, S.X. Wang, L. Jiang, and et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification Clin J Am Soc Nephrol 6 2011 2175 2184
29. R. Katafuchi, T. Ninomiya, M. Nagata, and et al. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation Clin J Am Soc Nephrol 6 2011 2806 2813
30. S. Barbour, M. Beaulieu, J. Gill, and et al. The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists Clin Kidney J 7 2014 538 545
31. A.S. Levey, J.P. Bosch, J.B. Lewis, and et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
32. L.E. Chambless, C.P. Cummiskey, and G. Cui Several methods to assess improvement in risk prediction models: extension to survival analysis Stat Med 30 2011 22 38
33. M.J. Pencina, R.B. D'Agostino, K.M. Pencina, and et al. Interpreting incremental value of markers added to risk prediction models Am J Epidemiol 176 2012 473 481
34. M.J. Pencina, R.B. D'Agostino, and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
35. J. Amrhein Introduction to frailty models. Proceedings of the SAS Global Forum 2014 Conference Available at: http://support.sas.com/resources/papers/proceedings14/1492-2014.pdf 2014 SAS Institute Inc Washington, DC 1492 2014
36. D. Kleinbaum, and M. Klein Survival Analysis 2nd ed. 2005 Springer Science New York